Ackman’s ‘wolf pack’ drove Allergan into foreign hands, former CEO says

Carly Helfand Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. ...

Report: Parexel layoffs include up to 200 ex-GlaxoSmithKline staffers

John Carroll When GlaxoSmithKline reported last December that it was ripping into its R&D operations in Research Triangle Park, NC, and laying off 900 staffers, the pharma giant ...

With solid Q2, Sanofi CEO says M&A could be part of growth strategy

Eric Palmer Sanofi's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take ...

Sanofi and Regeneron line up for second place in EU cardio race

Damian Garde Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make ...

Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key ...

UPDATED: Biogen R&D chief Doug Williams joins exodus to run a biotech upstart

John Carroll Biogen's high-profile R&D chief, Doug Williams, has heard the siren song of a biotech startup. Near midday on Friday, the Big Biotech put out word that Williams ...

Fast-growing Celgene snaps up Merck’s abandoned NJ campus

Tracy Staton Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old ...

Generics maker Alvogen eyes faster growth after CVC-led buyout

Tracy Staton A group of investment funds has teamed up to buy generics maker Alvogen. A consortium led by CVC Capital Partners snapped up a majority stake in the NJ-based company, in ...

Jury sides with Merck and its execs in gender-bias case

Tracy Staton Merck & Co. won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated ...

New standout Imbruvica data bode well for market expansion in CLL

Carly Helfand Johnson & Johnson and AbbVie's Imbruvica has already shown in one Phase III study that it can extend progression-free survival in patients with previously treated ...

Perrigo will talk tie-up if the price is right, CEO says–but Mylan has a ways to go

Carly Helfand Perrigo's not opposed to striking a pact with Mylan–as long as the price is right. The bad news for its suitor, though, is that right now, it's nowhere close. FiercePharma ...

FDA staffers raise doubts over key Vertex combo

Carly Helfand As an FDA review nears for Vertex's Kalydeco-lumacaftor tandem–approval of which could help Kalydeco reach 10 times the number of cystic fibrosis patients it ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS